Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
GRAL Stock Forecast 2025-2026
$46.72
Current Price
$1.68B
Market Cap
Buy 1
Hold 3
Sell 0
Wall St Analyst Ratings
Distance to GRAL Price Targets
-8.0%
To High Target of $43.00
-13.3%
To Median Target of $40.50
-18.7%
To Low Target of $38.00
GRAL Price Momentum
-5.1%
1 Week Change
+21.8%
1 Month Change
+216.7%
1 Year Change
+161.7%
Year-to-Date Change
-27.0%
From 52W High of $63.99
+278.9%
From 52W Low of $12.33
📊 TOP ANALYST CALLS
Did GRAL Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if GRAIL, Inc. is one of their latest high-conviction picks.
Latest GRAL Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, GRAL has a neutral consensus with a median price target of $40.50 (ranging from $38.00 to $43.00). The overall analyst rating is Buy (7.0/10). Currently trading at $46.72, the median forecast implies a -13.3% downside. This outlook is supported by 1 Buy, 3 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Kyle Mikson at Canaccord Genuity, projecting a 8.0% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GRAL Analyst Ratings
1
Buy
3
Hold
0
Sell
GRAL Price Target Range
Low
$38.00
Average
$40.50
High
$43.00
Current: $46.72
Latest GRAL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GRAL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 14, 2025 | Canaccord Genuity | Kyle Mikson | Buy | Maintains | $43.00 |
| Apr 21, 2025 | Canaccord Genuity | Kyle Mikson | Buy | Initiates | $32.00 |
| Mar 18, 2025 | Morgan Stanley | Tejas Savant | Equal-Weight | Maintains | $20.00 |
| Nov 27, 2024 | Morgan Stanley | Tejas Savant | Equal-Weight | Initiates | $16.00 |
| Oct 17, 2024 | Guggenheim | Subbu Nambi | Neutral | Initiates | $0.00 |
Grail, Inc. (GRAL) Competitors
The following stocks are similar to GRAIL, Inc. based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Grail, Inc. (GRAL) Financial Data
Grail, Inc. has a market capitalization of $1.68B with a P/E ratio of -0.7x. The company generates $130.71M in trailing twelve-month revenue with a -62.1% profit margin.
Revenue growth is +19.1% quarter-over-quarter, while maintaining an operating margin of -482.6% and return on equity of -62.2%.
Valuation Metrics
Market Cap
$1.68B
Enterprise Value
$1.24B
P/E Ratio
-0.7x
PEG Ratio
0.0x
Price/Sales
12.9x
Growth & Margins
Revenue Growth (YoY)
+19.1%
Gross Margin
-62.6%
Operating Margin
-482.6%
Net Margin
-62.1%
EPS Growth
+19.1%
Financial Health
Cash/Price Ratio
+40.1%
Current Ratio
9.7x
Debt/Equity
2.7x
ROE
-62.2%
ROA
-12.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Grail, Inc. (GRAL) Business Model
About Grail, Inc.
What They Do
Develops blood tests for early cancer detection.
Business Model
Grail Inc. generates revenue by commercializing innovative blood tests that detect multiple types of cancer through a single blood draw. Their flagship product, the Galleri test, leverages advanced sequencing technology and data science to provide critical diagnostic information, enabling early intervention and treatment.
Additional Information
As a pioneer in precision medicine, Grail Inc. aims to reduce cancer mortality rates and is positioned within the health technology and biotech sectors, attracting investor interest in healthcare innovation. The company is headquartered in Menlo Park, California.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
1,000
CEO
Mr. Robert P. Ragusa
Country
United States
IPO Year
2024
Website
grail.comGrail, Inc. (GRAL) Latest News & Analysis
Latest News
Quick Summary
DHL and other companies are leveraging technology breakthroughs to automate the loading and unloading processes, reducing labor intensity and injury risks.
Why It Matters
Automation in logistics reduces labor costs and injuries, enhancing efficiency and profitability for companies like DHL, potentially boosting investor confidence and stock performance.
Source: WSJ
Market Sentiment:
Positive
GRAIL Announces Positive Top-Line Results From The Galleri® PATHFINDER 2 Registrational Study
19 days ago
Quick Summary
GRAIL, Inc. reported positive results from the PATHFINDER 2 study, showing higher cancer detection and positive predictive value in an analysis of 25,578 participants.
Why It Matters
GRAIL's positive results in cancer detection may boost its stock value, enhance credibility, and attract investments, indicating strong market potential and innovation in healthcare.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Grail's shares increased following the announcement of improved results from the second study of its Galleri multi-cancer early detection test.
Why It Matters
Grail's rising shares indicate growing investor confidence in its Galleri test, potentially leading to increased market share and revenue in the healthcare sector.
Source: Market Watch
Market Sentiment:
Positive
These 24 Stocks Are Ripe for a Short Squeeze
25 days ago
Quick Summary
Recent negative sentiment in the stock market has led to significant returns from short squeezes. Investors may find opportunities in this trend.
Why It Matters
Negative sentiment can create volatility, leading to short squeezes. These can result in rapid price increases, presenting significant profit opportunities for investors who identify them early.
Source: Schaeffers Research
Market Sentiment:
Neutral
Quick Summary
The medical technology industry has emerged as a leader as the broader market rebounds from April lows, highlighting its innovation and growth potential.
Why It Matters
The medical technology industry's emergence as a leader indicates potential investment opportunities and growth, signaling a shift in market dynamics that could influence portfolio strategies.
Source: MarketBeat
Market Sentiment:
Positive
Quick Summary
GRAIL, Inc. granted 77,350 RSUs to 38 new non-executive employees as an employment inducement, enhancing its workforce focused on early cancer detection.
Why It Matters
GRAIL's equity awards signal confidence in growth and attract talent, potentially enhancing innovation and operational success, impacting stock performance positively.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About GRAL Stock
What is Grail, Inc.'s (GRAL) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, Grail, Inc. (GRAL) has a median price target of $40.50. The highest price target is $43.00 and the lowest is $38.00.
Is GRAL stock a good investment in 2026?
According to current analyst ratings, GRAL has 1 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $46.72. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for GRAL stock?
Wall Street analysts predict GRAL stock could reach $40.50 in the next 12 months. This represents a -13.3% decrease from the current price of $46.72. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Grail, Inc.'s business model?
Grail Inc. generates revenue by commercializing innovative blood tests that detect multiple types of cancer through a single blood draw. Their flagship product, the Galleri test, leverages advanced sequencing technology and data science to provide critical diagnostic information, enabling early intervention and treatment.
What is the highest forecasted price for GRAL Grail, Inc.?
The highest price target for GRAL is $43.00 from Kyle Mikson at Canaccord Genuity, which represents a -8.0% decrease from the current price of $46.72.
What is the lowest forecasted price for GRAL Grail, Inc.?
The lowest price target for GRAL is $38.00 from at , which represents a -18.7% decrease from the current price of $46.72.
What is the overall GRAL consensus from analysts for Grail, Inc.?
The overall analyst consensus for GRAL is neutral. Out of 3 Wall Street analysts, 1 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $40.50.
How accurate are GRAL stock price projections?
Stock price projections, including those for Grail, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 7, 2025 4:48 PM UTC